Propanc Biopharma, Inc. (OTCMKTS:PPCB – Get Free Report) shares fell 15.9% on Wednesday . The stock traded as low as $5.68 and last traded at $5.68. 432 shares were traded during mid-day trading, an increase of 2% from the average session volume of 425 shares. The stock had previously closed at $6.75.
Propanc Biopharma Trading Down 15.9 %
The business’s 50-day moving average is $6.43 and its 200-day moving average is $2.25.
About Propanc Biopharma
Propanc Biopharma, Inc, a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.
Featured Articles
- Five stocks we like better than Propanc Biopharma
- What is the Shanghai Stock Exchange Composite Index?
- Energy Transfer: Powering Data With Dividends and Diversification
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Qualcomm Stock Is Coiling for a Breakout
- How to Invest in Small Cap Stocks
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
